-
CHMP highlights: April 2021
CHMP highlights: April 2021
-
CHMP highlights: April 2021
CHMP highlights: April 2021
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its 19-22 April 2021 meeting
-
Clinical trial information system reaches major milestone
Clinical trial information system reaches major milestone
-
Clinical trial information system reaches major milestone
Clinical trial information system reaches major milestone
EMA’s Management Board confirms CTIS, one of the main deliverables of the Clinical Trial Regulation, is on track to go live by 31 January 2022.
-
Outcome of the PRAC review of COVID-19 Vaccine Janssen
Outcome of the PRAC review of COVID-19 Vaccine Janssen
-
Outcome of the PRAC review of COVID-19 Vaccine Janssen
Outcome of the PRAC review of COVID-19 Vaccine Janssen
EMA’s safety committee (PRAC) finds possible link to very rare cases of unusual blood clots with low blood platelets but overall benefit-risk remains positive
-
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA continues to monitor COVID-19 vaccine AstraZeneca
-
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA continues to monitor COVID-19 vaccine AstraZeneca
EMA to provide further context on risk of very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria
